Related Experiment Video
Updated: Aug 23, 2025
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
The potential of miR-153 as aggressive prostate cancer biomarker
Irina Gilyazova1, Elizaveta Ivanova1, Mikhail Sinelnikov2
1Institute of Biochemistry and Genetics, Ufa Federal Research Center of the Russian Academy of Sciences, 450054, Ufa, Russia.
Introduction:
Prostate cancer (PC) is one of the most frequently diagnosed cancers in males. MiR-153, as a member of the microRNA (miRNA) family, plays an important role in PC. This study aims to explore the expression and possible molecular mechanisms of the miR-153 action.
Methods:
Formalin-fixed paraffin-embedded (FFPE) tissues were collected from prostatectomy specimens of 29 metastatic and 32 initial stage PC patients. Expression levels of miR-153 were measured using real-time reverse transcription polymerase chain reaction (qRT-PCR). 2-ΔΔCT method was used for quantitative gene expression assessment. The candidate target genes for miR-153 were predicted by TargetScan. Mutations in target genes of miR-153 were identified using exome sequencing. Protein-protein interaction (PPI) networks, Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed to investigate the potential molecular mechanisms of miR-153 in PC.
Results:
MiR-153 was significantly up-regulated in PC tissues compared to non-cancerous tissues. The analysis of correlation between the expression level of miR-153 and clinicopathological factors revealed a statistically significant correlation with the stage of the tumor process according to tumor, node, metastasis (TNM) staging system (p = 0.0256). ROC curve analysis was used to evaluate the predictive ability of miR-153 for metastasis development and it revealed miR-153 as a potential prognostic marker (AUC = 0.85; 95%CI 0.75-0.95; sensitivity = 0.72, specificity = 0.86)). According to logistic regression model the high expression of miR-153 increased the risk of metastasis development (odds ratios = 3.14, 95% CI 1.62-8.49; p-value = 0.006). Whole exome sequencing revealed nonsynonymous somatic mutations in collagen type IV alpha 1 (COL4A1), collagen type IV alpha 3 (COL4A3), forkhead box protein O1 (FOXO1), 2-hydroxyacyl-CoA lyase 1 (HACL1), hypoxia-inducible factor 1-alpha (HIF-1A), and nidogen 2 (NID2) genes. Moreover, KEGG analysis revealed that the extracellular matrix-receptor (ECM-receptor) interaction pathway is mainly involved in PC.
Conclusion:
MiR-153 is up-regulated in PC tissues and may play an important role in aggressive PC by targeting potential target genes.
Insights
MicroRNA-153 (miR-153) is elevated in prostate cancer (PC) tissues and is linked to tumor stage and metastasis. This microRNA may serve as a prognostic marker for aggressive PC.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Prostate cancer (PC) is a prevalent malignancy in males.
- MicroRNAs (miRNAs), including miR-153, are implicated in PC development and progression.
- Understanding miR-153's role is crucial for identifying potential therapeutic targets.
Purpose of the Study:
- To investigate the expression levels of miR-153 in prostate cancer tissues.
- To explore the potential molecular mechanisms and target genes of miR-153 in PC.
- To assess the prognostic value of miR-153 in predicting PC metastasis.
Main Methods:
- Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) was used to measure miR-153 expression in 61 PC tissues.
- TargetScan was employed to predict miR-153 target genes, followed by exome sequencing to identify mutations.
- Bioinformatic analyses, including KEGG and PPI networks, were performed to elucidate molecular pathways.
Main Results:
- MiR-153 was significantly upregulated in PC tissues compared to non-cancerous tissues.
- High miR-153 expression correlated with advanced tumor stage (TNM) and increased risk of metastasis (OR=3.14).
- Exome sequencing identified mutations in key genes (e.g., COL4A1, FOXO1, HIF-1A), and KEGG analysis highlighted the ECM-receptor interaction pathway.
Conclusions:
- MiR-153 is upregulated in prostate cancer and associated with aggressive disease.
- MiR-153 demonstrates potential as a prognostic biomarker for PC metastasis.
- Targeting miR-153 and its associated pathways may offer new therapeutic strategies for advanced PC.
